Literature DB >> 12487838

Antithrombin supplementation III in childhood acute lymphoblastic leukemia treated with L-asparaginase.

Akinobu Matsuzaki, Aiko Suminoe, Toshiro Hara.   

Abstract

The change of plasma antithrombin III (AT) levels after supplementation of AT concentrates was examined in ALL children with acquired AT deficiency following L-asparaginase (ASP) administration. The patients received AT concentrates of 34.5 +/- 7.6 U/kg. The increase of plasma AT activity and antigen was 2.07 +/- 0.62% and 0.70 +/- 0.16 mg/dL per unit AT infused per kilogram of body weight, respectively. The activity decreased to 62.0 +/- 7.7% of the peak values by 48 hours after supplementation. The administration of AT concentrates constantly increased the plasma AT activity in ALL children treated with ASP, which may minimize the acquired prothrombotic state.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12487838     DOI: 10.1080/08880010290108744

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  3 in total

1.  Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates.

Authors:  Giancarlo Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2009-10       Impact factor: 3.443

2.  Population pharmacokinetics of human antithrombin concentrate in paediatric patients.

Authors:  Brady S Moffett; Rosa Diaz; Marianne Galati; Donald Mahoney; Jun Teruya; Donald L Yee
Journal:  Br J Clin Pharmacol       Date:  2017-08-11       Impact factor: 4.335

Review 3.  Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options.

Authors:  Peter S Maclean; R Campbell Tait
Journal:  Drugs       Date:  2007       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.